Androstenedione is the preferred androgen source in hormone refractory prostate cancer-Response

Christopher Hovens; Matthew Hong; Niall Corcoran

doi:10.1158/1078-0432.CCR-14-1536

Androstenedione is the preferred androgen source in hormone refractory prostate cancer-Response

Christopher Hovens
, Matthew Hong
, Niall Corcoran

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	4972-4973
Number of pages	2
Journal	Clinical Cancer Research
Volume	20
Issue number	18
DOIs	https://doi.org/10.1158/1078-0432.CCR-14-1536
Publication status	Published - 15 Sept 2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1158/1078-0432.CCR-14-1536Licence: In Copyright

Cite this

@article{50b9829b2a7b456e8f1e8a35f6fac14c,

title = "Androstenedione is the preferred androgen source in hormone refractory prostate cancer-Response",

author = "Christopher Hovens and Matthew Hong and Niall Corcoran",

year = "2014",

month = sep,

day = "15",

doi = "10.1158/1078-0432.CCR-14-1536",

language = "English",

volume = "20",

pages = "4972--4973",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research",

number = "18",

}

TY - JOUR

T1 - Androstenedione is the preferred androgen source in hormone refractory prostate cancer-Response

AU - Hovens, Christopher

AU - Hong, Matthew

AU - Corcoran, Niall

PY - 2014/9/15

Y1 - 2014/9/15

UR - https://www.scopus.com/pages/publications/84907912503

U2 - 10.1158/1078-0432.CCR-14-1536

DO - 10.1158/1078-0432.CCR-14-1536

M3 - Letter

SN - 1078-0432

VL - 20

SP - 4972

EP - 4973

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 18

ER -

Androstenedione is the preferred androgen source in hormone refractory prostate cancer-Response

UN SDGs

Access to Document

Other files and links

Cite this